The Protective Arm of the Renin Angiotensin System: Functional Aspects and Therapeutic Implications is the first comprehensive publication to signal the protective role of a distinct part of the renin-angiotensin system (RAS), providing readers with early insight into a complex system which will become of major medical importance in the near future. Focusing on recent research, The Protective Arm of the Renin Angiotensin System presents a host of new experimental studies on specific components of the RAS, namely angiotensin AT2 receptors (AT2R), the angiotensin (1-7) peptide with its receptor Mas, and the enzyme ACE 2, which exert significant beneficial, health-promoting actions by counterbalancing the well-known harmful arm of the RAS with its classical angiotensin AT1 receptor. This innovative concept of the protective arm of the RAS, examined in this reference, represents an indispensable background and will be a strong support for biomedical students, researchers, cardiologists, surgeons, nephrologists, diabetologists, and endocrinologists, as well as any other physician or researcher concerned with RAS physiology, pathophysiology and clinical implications.
- Provides a complete understanding of the protective side of the Renin Angiotensin System (RAS) involving angiotensin AT2 receptor, ACE2, and Ang(1-7)/Mas receptor
- Combines the knowledge of editors who pioneered research on the protective renin angiotensin system including; Dr. Thomas Unger, one of the founders of AT2 receptor research; Dr. Ulrike M. Steckelings, who contributed significantly to first preclinical studies with a novel specific AT2-agonist, and Dr. Robson Santos who pioneered research on angiotensin-(1-7) and its receptor Mas.
- Shows that the protective RAS axes are able to ameliorate the course of several cardiovascular, renal, metabolic and neurological diseases
- Provides the basis for the understanding of a novel therapeutic approach to stimulate components of the protective arm of the RAS.
The Protective Arm of the Renin Angiotensin System: Functional Aspects and Therapeutic Implications is the first comprehensive publication to signal the protective role of a distinct part of the renin-angiotensin system (RAS), providing readers with early insight into a complex system which will become of major medical importance in the near future. Focusing on recent research, The Protective Arm of the Renin Angiotensin System presents a host of new experimental studies on specific components of the RAS, namely angiotensin AT2 receptors (AT2R), the angiotensin (1-7) peptide with its receptor Mas, and the enzyme ACE 2, which exert significant beneficial, health-promoting actions by counterbalancing the well-known harmful arm of the RAS with its classical angiotensin AT1 receptor. This innovative concept of the protective arm of the RAS, examined in this reference, represents an indispensable background and will be a strong support for biomedical students, researchers, cardiologists, surgeons, nephrologists, diabetologists, and endocrinologists, as well as any other physician or researcher concerned with RAS physiology, pathophysiology and clinical implications. Provides a complete understanding of the protective side of the Renin Angiotensin System (RAS) involving angiotensin AT2 receptor, ACE2, and Ang(1-7)/Mas receptor Combines the knowledge of editors who pioneered research on the protective renin angiotensin system including; Dr. Thomas Unger, one of the founders of AT2 receptor research; Dr. Ulrike M. Steckelings, who contributed significantly to first preclinical studies with a novel specific AT2-agonist, and Dr. Robson Santos who pioneered research on angiotensin-(1-7) and its receptor Mas. Shows that the protective RAS axes are able to ameliorate the course of several cardiovascular, renal, metabolic and neurological diseases Provides the basis for the understanding of a novel therapeutic approach to stimulate components of the protective arm of the RAS.
Contributors
Marie-Isabel Aguilar Department of Biochemistry and Molecular Biology, Monash University, Clayton Victoria 3800, Australia
Natalia Alenina
Max-Delbrueck-Center for Moleculare Medicine (MDC), Berlin-Buch, Germany
Federal University of Minas Gerais, Belo Horizonte, Brazil
Instituto Nacional de Ciência e Tecnologia em, NanoBiofarmacêutica (NanoBIOFAR), Belo Horizonte, Brazil
Peter W. Angus Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
Michael Bader
Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany
Charité Medical Faculty, Berlin, Germany
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Institute for Biology, University of Lübeck, Germany
Ana Paula Correa Oliveira Bahia Departamento de Fisiologia e Biofísica—ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Dhaniel Baraldi Department of Pharmacology, Monash University, Clayton Victoria 3800, Australia
Lívia Corrêa Barroso Departamento de Bioquimica e Imunologia, UFMG, Belo Horizonte, Minas Gerais, Brazil
Lenice Becker Sport Center of UFOP, Federal University of Ouro Preto, Ouro Preto, Minas Gerais, Brazil
Douglas M. Bennion Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida, USA
Serge P. Bottari
Laboratory for Fundamental and Applied Bioenergetics, INSERM U1055, Université Grenoble—Alpes
Radioanalysis Unit, Institute for Biology and Pathology, CHU de Grenoble, Grenoble, France
Peter Buehlmayer Hangstrasse 18, CH-4144 Arlesheim, Switzerland
Maria J. Campagnole-Santos Department of Physiology and Biophysics, INCT-Nanobiofar, Institute of Biological Sciences, Federal University of Minas Gerais-UFMG, Brazil
Robert M. Carey Department of Medicine, University of Virginia, Charlottesville, Virginia, USA
Harshita Chodavarapu Department of Pharmacology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
Leoluca Criscione MangiaSano Consulting, Rümelinbachweg 10, CH-4054 Basel, Switzerland
Juraj Culman Institute of Experimental and Clinical Pharmacology, University Hospitals of Schleswig-Holstein, Campus Kiel, Kiel, Germany
Björn Dahlöf Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Gothenburg, Sweden
Leon Alexander Danyel Center for Cardiovascular Research (CCRI), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Germany
Marc de Gasparo Cardiovascular & Metabolic Syndrome Adviser, Rossemaison, Switzerland
Mark Del Borgo Department of Biochemistry and Molecular Biology, Monash University, Clayton Victoria 3800, Australia
Kate M. Denton Department of Physiology, Monash University, Clayton Victoria 3800, Australia
Isha S. Dhande University of Hosuton, Houston, Texas, USA
Gere S. diZerega
US Biotest, San Luis Obispo
Keck School of Medicine, Los Angeles, CA, USA
Fernando Pablo Dominici Department of Biological Chemistry, IQUIFIB, University of Buenos Aires, Buenos Aires, Argentina
Adelina M. dos Reis Department of Physiology & Biophysics, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Victor J. Dzau Institute of Medicine of the National Academies, Washington, DC, USA
Veronica Valero Esquitino Center for Cardiovascular Research (CCRI), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Germany
Anderson J. Ferreira Department of Morphology, Federal University of Minas Gerais, Belo Horizonte, MG 31270-901, Brazil
Anna Foryst-Ludwig Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Berlin, Germany
Sébastien Foulquier CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands
Rodrigo A. Fraga-Silva Institute of Bioengineering, Ecole Polytechnique Federale de Lausanne, Lausanne, Vaud, Switzerland
Frédéric Frézard Departamento de Fisiologia e Biofísica—ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Pascal Furet Novartis Institute for Biochemical Research, CH-4002 Basel, Switzerland
Patricia E. Gallagher Hypertension and Vascular Research Center, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
Lie Gao Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, USA
Tracey A. Gaspari Department of Pharmacology, Monash University, Clayton Victoria 3800, Australia
Mariela M. Gironacci Department of Biological Chemistry, IQUIFIB-CONICET, University of Buenos Aires, Buenos Aires, Argentina
Anders Hallberg Department of Medicinal Chemistry, Division of Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, Sweden
Chandana B. Herath Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
Lucinda M. Hilliard Department of Physiology, Monash University, Clayton Victoria 3800, Australia
Masatsugu Horiuchi Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Shitsukawa, Ehime, Japan
Tahir Hussain University of Hosuton, Houston, Texas, USA
Rebecka Isaksson Department of Medicinal Chemistry, Division of Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, Sweden
Emma S. Jones Department of Pharmacology, Monash University, Clayton Victoria 3800, Australia
Elena Kaschina Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Berlin, Germany
Michael Katovich Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
Ulrich Kintscher Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Berlin, Germany
Mats Larhed Department of Medicinal Chemistry, Division of Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, Sweden
Eric Lazartigues Department of Pharmacology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
Kai Y. Mak Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
Nephtali Marina Department of Clinical Pharmacology and Experimental Therapeutics, University College London, London,...
Erscheint lt. Verlag | 18.4.2015 |
---|---|
Sprache | englisch |
Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Endokrinologie |
Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie | |
Studium ► 1. Studienabschnitt (Vorklinik) ► Physiologie | |
ISBN-10 | 0-12-801485-7 / 0128014857 |
ISBN-13 | 978-0-12-801485-1 / 9780128014851 |
Haben Sie eine Frage zum Produkt? |
![PDF](/img/icon_pdf_big.jpg)
Größe: 20,9 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
![EPUB](/img/icon_epub_big.jpg)
Größe: 11,6 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich